Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Firibastat · QGC-001, RB-150

Small molecule · developed by Quantum Genomics SA

Phase 3 Most advanced trial (none active)

QNTM Developer

4 Registered trials

What is Firibastat?

Firibastat is an investigational small-molecule drug studied in Essential Hypertension, Hypertension, Hypertension (HTN).

At a glance

Also known as: QGC-001, RB-150
Drug type: Small molecule
Therapy area: Cardiovascular
Developer: Quantum Genomics SA (QNTM, QUCY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 638KY4573I

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04857840	Phase 3	Hypertension (HTN)	Terminated	QNTM
NCT04277884	Phase 3	Hypertension	Completed	QNTM
NCT03198793	Phase 2	Hypertension	Completed	QNTM
NCT01900171	Phase 1	Essential Hypertension	Completed	QNTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Essential HypertensionHypertensionHypertension (HTN)

More from Quantum Genomics SA

FSD-201 Phase 2 Lucid-21-302 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the QNTM page.

Follow QNTM, the company behind Firibastat

See QNTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

QNTM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z